DK3395338T3 - Hurtigt opløsende formulering af cinacalcet-hcl - Google Patents

Hurtigt opløsende formulering af cinacalcet-hcl Download PDF

Info

Publication number: DK3395338T3
Authority: DK; Denmark
Prior art keywords: cinacalcet; hcl; formulation; quick; quick solving
Prior art date: 2003-09-12

Application number

DK18175495.3T

Other languages

English (en)

Inventor

Tzuchi R Ju

Hung-Ren H Lin

Glen Cary Lawrence

Francisco J Álvarez

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-12

Filing date

2004-09-10

Publication date

2019-07-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3395338(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-09-10 Application filed by Amgen Inc filed Critical Amgen Inc

2019-07-22 Application granted granted Critical

2019-07-22 Publication of DK3395338T3 publication Critical patent/DK3395338T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK18175495.3T 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl DK3395338T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50221903P	2003-09-12	2003-09-12
EP17185704.8A EP3260117B8 (en)	2003-09-12	2004-09-10	Rapid dissolution formulation comprising cinacalcet hcl

Publications (1)

Publication Number	Publication Date
DK3395338T3 true DK3395338T3 (da)	2019-07-22

Family

ID=34434844

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
DK18175495.3T DK3395338T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet-hcl
DK18175497.9T DK3395339T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet-hcl
DK04781429.8T DK1663182T4 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet HCI
DK14163366.9T DK2821067T3 (da)	2003-09-12	2004-09-10	Hurtigopløsningsformulering af cinacalcet
DK18175499.5T DK3395340T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet-hcl
DK17185704.8T DK3260117T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering, der omfatter cinacalcet-hcl

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
DK18175497.9T DK3395339T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet-hcl
DK04781429.8T DK1663182T4 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet HCI
DK14163366.9T DK2821067T3 (da)	2003-09-12	2004-09-10	Hurtigopløsningsformulering af cinacalcet
DK18175499.5T DK3395340T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering af cinacalcet-hcl
DK17185704.8T DK3260117T3 (da)	2003-09-12	2004-09-10	Hurtigt opløsende formulering, der omfatter cinacalcet-hcl

Country Status (30)

Country	Link
US (7)	US7829595B2 (da)
EP (8)	EP1663182B2 (da)
JP (3)	JP5026077B2 (da)
KR (1)	KR101332058B1 (da)
CN (1)	CN1946382B (da)
AR (1)	AR045637A1 (da)
AU (1)	AU2004279318C1 (da)
BR (2)	BRPI0414254B8 (da)
CA (1)	CA2536487C (da)
CY (5)	CY1119609T1 (da)
DE (1)	DE19164145T1 (da)
DK (6)	DK3395338T3 (da)
EA (1)	EA013425B1 (da)
ES (7)	ES2734057T3 (da)
HR (1)	HRP20130114T4 (da)
HU (5)	HUE044822T2 (da)
IL (1)	IL173737A (da)
IS (1)	IS3027B (da)
MX (1)	MXPA06002616A (da)
MY (1)	MY142046A (da)
NO (1)	NO335739B1 (da)
NZ (1)	NZ545498A (da)
PL (6)	PL3395339T3 (da)
PT (6)	PT3395340T (da)
SG (1)	SG146608A1 (da)
SI (6)	SI3395340T1 (da)
TR (4)	TR201909267T4 (da)
TW (1)	TWI344363B (da)
WO (1)	WO2005034928A1 (da)
ZA (1)	ZA200602710B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
BRPI0414254B8 (pt)	2003-09-12	2021-05-25	Amgen Inc	composição farmacêutica compreendendo hcl de cinacalceto
NZ587547A (en)	2004-06-24	2012-09-28	Vertex Pharma	Modulators of ATP-Binding Cassette Transporters
KR20070116286A (ko) *	2005-05-16	2007-12-07	테바 파마슈티컬 인더스트리즈 리미티드	시나칼셋 염산염의 제조 방법
EP1883625A2 (en) *	2005-05-23	2008-02-06	Teva Pharmaceutical Industries Ltd	Amorphous cinacalcet hydrochloride and preparation thereof
CA2605736A1 (en) *	2005-05-23	2006-11-30	Teva Pharmaceutical Industries Ltd.	Purification of cinacalcet
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물
WO2007027548A2 (en) *	2005-09-02	2007-03-08	Amgen Inc.	Methods of modulating intestinal fluid balance
US7563930B2 (en) *	2005-11-22	2009-07-21	Teva Pharmaceutical Industries Ltd	Crystal forms of Cinacalcet HCI and processes for their preparation
HUE032813T2 (en)	2005-12-28	2017-11-28	Vertex Pharma	Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE029572T2 (en)	2006-02-03	2017-03-28	Opko Renal Llc	Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3
MX2008012061A (es) *	2006-03-23	2008-12-17	Amgen Inc	Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
TW200811082A (en) *	2006-04-27	2008-03-01	Teva Pharma	Process for the preparation of cinacalcet base
KR20090025189A (ko) *	2006-04-27	2009-03-10	테바 파마슈티컬 인더스트리즈 리미티드	시나칼셋 염기의 제조 방법
ES2791535T3 (es)	2006-06-21	2020-11-04	Opko Ireland Global Holdings Ltd	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
EP2069285A1 (en) *	2006-06-27	2009-06-17	Sandoz AG	Amorphous form of cinacalcet
CA2662315A1 (en) *	2006-09-01	2008-03-06	Teva Pharmaceutical Industries Ltd.	Solid composites of a calcium receptor-active compound
EP1968932A1 (en) *	2006-11-20	2008-09-17	Teva Pharmaceutical Industries Ltd.	Process for preparing cinacalcet
WO2008064202A2 (en) *	2006-11-20	2008-05-29	Dr. Reddy's Labortories, Ltd.	Modified-release formulations of calcium receptor-active compounds
TWI573802B (zh)	2007-03-06	2017-03-11	安美基公司	變異之活動素受體多肽及其用途
CA2701638A1 (en) *	2007-04-02	2008-10-09	Concert Pharmaceuticals Inc.	Pharmaceutical calcimimetics
CN101668532B (zh)	2007-04-25	2014-08-20	赛特克罗公司	治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
PL2148661T3 (pl)	2007-04-25	2013-07-31	Cytochroma Inc	Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
MX2009014104A (es) *	2007-06-21	2010-04-21	Amgen Inc	Metodos para sintetizar cinacalcet y sales del mismo.
WO2009025792A2 (en) *	2007-08-16	2009-02-26	Teva Pharmaceutical Industries Ltd.	Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
US20090275780A1 (en) *	2008-05-05	2009-11-05	Medichem, S.A.	Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
WO2010034497A2 (de)	2008-09-25	2010-04-01	Ratiopharm Gmbh	Kompaktiertes cinacalcet
WO2010086129A1 (en)	2009-01-27	2010-08-05	Rathiopharm Gmbh	Inclusion complex comprising cinacalcet and cyclodextrin
LT2821400T (lt)	2009-03-20	2018-02-12	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas
WO2010136035A2 (en)	2009-05-27	2010-12-02	Leo Pharma A/S	Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136037A1 (en)	2009-05-27	2010-12-02	Leo Pharma A/S	Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de)	2009-10-21	2011-04-27	Ratiopharm GmbH	Schmelzgranuliertes Cinacalcet
CA2797537C (en)	2010-03-29	2021-11-23	Cytochroma Inc.	Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
EP2603215A4 (en)	2010-08-11	2015-08-05	Philadelphia Health & Educatio	NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
PT2642980T (pt) *	2010-11-23	2020-06-24	Amgen Inc	Formulação pediátrica
US20130267516A1 (en)	2010-11-26	2013-10-10	Leo Pharma A/S	Substituted cyclopentyl-azines as casr-active compounds
RU2013128981A (ru)	2010-11-26	2015-01-10	Лео Фарма А/С	Соединения, активные в отношении чувствительных к кальцию рецепторов
US20130261132A1 (en)	2010-11-26	2013-10-03	Leo Pharma A/S	Calcium-sensing receptor-active compounds
JP2014507375A (ja)	2010-11-26	2014-03-27	レオファーマアクティーゼルスカブ	カルシウム感知受容体活性化合物
SG11201403367YA (en) *	2011-12-19	2014-07-30	Amgen Inc	Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013107503A1 (en)	2012-01-17	2013-07-25	Zentiva Saglik Urunleri San. Ve Tic. A.S.	Method for producing cinacalcet compositions for direct tableting
CN109966264A (zh)	2012-02-27	2019-07-05	沃泰克斯药物股份有限公司	药物组合物及其施用
CN102885792A (zh) *	2012-10-12	2013-01-23	华润赛科药业有限责任公司	盐酸西那卡塞的口服固体速释制剂
EP2730279B1 (en) *	2012-11-09	2015-07-22	K.H.S. Pharma Holding GmbH	Immediate release formulations of cinacalcet
CN113842362A (zh)	2012-11-14	2021-12-28	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
BR112015014430B1 (pt) *	2012-12-21	2022-08-30	Synthon B.V.	Composição em comprimido
JP2016508504A (ja)	2013-02-01	2016-03-22	サンタマリアバイオセラピューティクスインコーポレイテッド	対象に対する抗アクチビン−ａ化合物の投与
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
CA2915432C (en) *	2013-06-26	2019-03-05	Jubilant Life Sciences Limited	Disintegrant free composition of cinacalcet
WO2015136329A1 (en) *	2014-03-14	2015-09-17	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical composition of cinacalcet
WO2015150944A1 (en)	2014-03-29	2015-10-08	Wockhardt Limited	Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) *	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
ES2702288T3 (es)	2014-10-07	2019-02-28	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
CN104721164B (zh) *	2015-03-25	2017-07-07	河北仁合益康药业有限公司	一种盐酸西那卡塞薄膜衣片组合物
SG11201808227YA (en)	2016-03-28	2018-10-30	Opko Ireland Global Holdings Limited	Methods of vitamin d treatment
US11413295B2 (en)	2016-03-31	2022-08-16	Intercept Pharmaceuticals, Inc.	Oral preparation of obeticholic acid
WO2019034981A1 (en) *	2017-08-16	2019-02-21	Unichem Laboratories Ltd	PHARMACEUTICAL COMPOSITIONS COMPRISING CINACALCET CHLORHYDRATE AND ONE OR MORE BINDERS
US20210030671A1 (en)	2018-03-30	2021-02-04	Ftf Pharma Private Limited	Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en)	2018-10-25	2021-02-16	Mark Mutchnik	Window seal for preventing water penetration
RU2750761C2 (ru) *	2019-09-17	2021-07-02	Общество с ограниченной ответственностью "АМЕДАРТ"	Ядро таблетки, содержащей цинакальцета гидрохлорид
IL295986A (en) *	2020-02-29	2022-10-01	Kempharm Inc	Preparations that include methylphenidate drugs, production processes and their use
CN112546010A (zh) *	2020-12-02	2021-03-26	普莱赛思(天津)生命科技有限公司	一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4517179A (en)	1983-04-29	1985-05-14	Pennwalt Corporation	Rapid dissolving, uniform drug compositions and their preparation
NZ226696A (en)	1987-11-02	1991-10-25	Merck & Co Inc	Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt%
EP0357815A1 (de)	1988-09-06	1990-03-14	Siemens Aktiengesellschaft	Schaltbare Konstantstromquelle mit I2L-Gattern
EP0373417A1 (en)	1988-11-30	1990-06-20	Schering Corporation	Sustained release diltiazem formulation
NZ231897A (en) *	1988-12-30	1992-09-25	Monsanto Co	Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) *	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
US4931286A (en)	1989-04-19	1990-06-05	Aqualon Company	High gloss cellulose tablet coating
DD299322A5 (de) *	1989-09-21	1992-04-09	Maschinenfabrik Rieter Ag,Ch	Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) *	1989-12-05	1991-04-30	Progressive Tool & Industries Co.	Automotive body framing system
EP1281702B1 (en)	1991-08-23	2005-12-21	Nps Pharmaceuticals, Inc.	Calcium receptor active molecules
US6011068A (en)	1991-08-23	2000-01-04	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
AU702629B2 (en)	1991-08-23	1999-02-25	Nps Pharmaceuticals, Inc.	Calcium receptor-active arylalkyl amines
US6031003A (en)	1991-08-23	2000-02-29	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US6313146B1 (en) *	1991-08-23	2001-11-06	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US6001884A (en)	1991-08-23	1999-12-14	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5162117A (en)	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
RU2146132C1 (ru)	1993-02-23	2000-03-10	Брихэм энд Уимен З Хоспитал, Инк.	Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция
US6210714B1 (en) *	1993-11-23	2001-04-03	Euro-Celtique S.A.	Immediate release tablet cores of acetaminophen having sustained-release coating
ZA956029B (en) *	1994-07-22	1997-01-20	Lilly Co Eli	Combination treatment for inhibiting bone loss
CN1312116C (zh)	1994-10-21	2007-04-25	Nps药物有限公司	钙受体活性化合物
GB9424766D0 (en)	1994-12-07	1995-02-08	Wellcome Found	Pharmaceutical composition
GB9501127D0 (en)	1995-01-20	1995-03-08	Wellcome Found	Tablet
DE19530575A1 (de)	1995-08-19	1997-02-20	Gruenenthal Gmbh	Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
DE69739388D1 (de)	1996-05-01	2009-06-10	Nps Pharma Inc	Inorganische am Ionen-Rezeptor aktive Verbindungen
US5837292A (en)	1996-07-03	1998-11-17	Yamanouchi Europe B.V.	Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR100860655B1 (ko)	1996-07-08	2008-09-26	기린 파마 가부시끼가이샤	칼슘 수용체 활성 화합물
DE19637082A1 (de)	1996-09-12	1998-03-19	Boehringer Mannheim Gmbh	Schnellzerfallende Pellets
TW483881B (en)	1996-12-03	2002-04-21	Nps Pharma Inc	Calcilytic compounds
IE970588A1 (en) *	1997-08-01	2000-08-23	Elan Corp Plc	Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de)	1997-08-13	1999-02-25	OCé PRINTING SYSTEMS GMBH	Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
DK1058538T3 (da)	1998-03-06	2002-10-21	Eurand Int	Hurtigt desintegrerende tabletter
US6525084B2 (en)	1998-07-23	2003-02-25	Novo Nordisk A/S	Stable pharmaceutical formulation
AU760889B2 (en)	1998-10-14	2003-05-22	Ortho-Mcneil Pharmaceutical, Inc.	1,2-disubstituted cyclopropanes
CZ304306B6 (cs) *	1998-11-23	2014-02-26	Monsanto Technology Llc	Vysoce koncentrované vodné glyfosátové kompozice
UA74141C2 (uk) *	1998-12-09	2005-11-15	Дж.Д. Сірл Енд Ко.	Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) *	1999-05-11	2002-09-10	Metagenics, Inc.	Composition for promoting healthy bone structure
US6733780B1 (en)	1999-10-19	2004-05-11	Genzyme Corporation	Direct compression polymer tablet core
FR2800735B1 (fr)	1999-11-09	2002-02-01	Centre Nat Rech Scient	Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
MXPA02006150A (es) *	1999-12-22	2004-09-06	Pharmacia Corp	Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
GB0001621D0 (en) *	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
EP1272181A2 (en) *	2000-04-13	2003-01-08	Synthon B.V.	Modified release formulations containing a hypnotic agent
US6419954B1 (en) *	2000-05-19	2002-07-16	Yamanouchi Pharmaceutical Co., Ltd.	Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr)	2000-05-24	2005-10-14	Centre Nat Rech Scient	Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) *	2000-06-30	2003-12-02	Yamanouchi Pharmaceutical Co., Ltd.	Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) *	2000-09-22	2002-06-11	Takeda Chem Ind Ltd	固形製剤
US20040034039A1 (en)	2000-09-22	2004-02-19	Yoshinori Nakano	Solid preparations
US7049283B2 (en) *	2000-12-06	2006-05-23	Novartis Ag	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (da) *	2001-05-17	2003-09-13	Sun Pharmaceutical Ind Ltd
MXPA03011922A (es)	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
EP1321142A1 (en)	2001-12-21	2003-06-25	Novartis AG	Solid pharmaceutical composition for oral administration of Tegaserod
AU2003238670A1 (en)	2002-04-05	2003-10-27	Cadila Healthcare Limited	Fast disintegrating oral dosage forms
US20050147670A1 (en) *	2002-05-29	2005-07-07	Impax Laboratories Inc.	Oral disintegrating dosage forms
WO2004030669A1 (en)	2002-09-30	2004-04-15	Schering Corporation	Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en)	2002-12-23	2003-01-29	Novartis Ag	Organic compounds
BRPI0414254B8 (pt)	2003-09-12	2021-05-25	Amgen Inc	composição farmacêutica compreendendo hcl de cinacalceto
CA2576659A1 (en)	2004-08-23	2006-03-02	Teva Pharmaceutical Industries Ltd.	Solid and crystalline ibandronate sodium and processes for preparation thereof
NL1028867C2 (nl)	2005-04-26	2006-10-27	Xycarb Ceramics B V	Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
US8922209B2 (en)	2008-03-11	2014-12-30	The University Of Western Ontario	System and method for magnetic resonance imaging

2004
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en active Application Filing
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/en not_active Expired - Lifetime
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh not_active Expired - Lifetime
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/en not_active Revoked
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en not_active IP Right Cessation
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es not_active Expired - Lifetime
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/en not_active Revoked
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja not_active Expired - Lifetime
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en not_active Expired
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es not_active Expired - Lifetime
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es not_active Expired - Lifetime
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh not_active IP Right Cessation
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es not_active Expired - Lifetime
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/en not_active Expired - Lifetime
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 EP EP10014567A patent/EP2316442A1/en not_active Withdrawn
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 CA CA2536487A patent/CA2536487C/en not_active Expired - Lifetime
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es not_active Expired - Lifetime
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es not_active Expired - Lifetime
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/da active
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/en not_active Revoked
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/en not_active Expired - Lifetime
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko active IP Right Grant
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/en not_active Revoked
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja not_active Expired - Lifetime
2013
- 2013-02-08 HR HRP20130114TT patent/HRP20130114T4/hr unknown
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja not_active Expired - Lifetime
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT3395338T (pt)	2019-07-23
HRP20130114T4 (hr)	2019-12-27
HUE043958T2 (hu)	2019-09-30
US7829595B2 (en)	2010-11-09
DK1663182T3 (da)	2013-04-15
JP2012197280A (ja)	2012-10-18
SI1663182T1 (sl)	2013-05-31
US20200222340A1 (en)	2020-07-16
KR20070017460A (ko)	2007-02-12
SI3395338T1 (sl)	2019-08-30
EP3260117B8 (en)	2019-11-27
CA2536487A1 (en)	2005-04-21
EP3260117B1 (en)	2019-04-17
PT3395340T (pt)	2019-07-15
EP2821067A1 (en)	2015-01-07
EP3578175B1 (en)	2022-11-30
ES2737348T3 (es)	2020-01-13
IS8324A (is)	2006-02-23
US20050147669A1 (en)	2005-07-07
US20160338975A1 (en)	2016-11-24
TWI344363B (en)	2011-07-01
TW200518743A (en)	2005-06-16
ES2655435T3 (es)	2018-02-20
KR101332058B1 (ko)	2013-11-22
MXPA06002616A (es)	2006-06-05
PL1663182T5 (pl)	2020-07-27
ES2812198T1 (es)	2021-03-16
US20190117592A1 (en)	2019-04-25
CY1122259T1 (el)	2020-11-25
EA013425B1 (ru)	2010-04-30
EP1663182B1 (en)	2013-01-16
EP3578175A1 (en)	2019-12-11
PL3260117T3 (pl)	2019-10-31
NZ545498A (en)	2010-04-30
NO20061640L (no)	2006-06-12
CY1121820T1 (el)	2020-07-31
ES2401769T5 (es)	2020-07-01
US9375405B2 (en)	2016-06-28
IL173737A0 (en)	2006-07-05
DE19164145T1 (de)	2021-04-29
TR201909267T4 (tr)	2019-07-22
DK1663182T4 (da)	2020-02-17
ES2735226T3 (es)	2019-12-17
EP3395338B1 (en)	2019-05-01
PT3260117T (pt)	2019-07-04
US20210052518A1 (en)	2021-02-25
HRP20130114T1 (en)	2013-03-31
SI3395339T1 (sl)	2019-08-30
US20180243238A1 (en)	2018-08-30
MY142046A (en)	2010-08-30
NO335739B1 (no)	2015-02-02
EP2316442A1 (en)	2011-05-04
HUE044279T2 (hu)	2019-10-28
EP2821067B1 (en)	2017-10-25
EP3395339B1 (en)	2019-04-17
SI3260117T1 (sl)	2019-08-30
ES2401769T3 (es)	2013-04-24
PL1663182T3 (pl)	2013-06-28
DK3395339T3 (da)	2019-07-22
EA200600566A1 (ru)	2006-08-25
CY1121814T1 (el)	2020-07-31
EP1663182A1 (en)	2006-06-07
SG146608A1 (en)	2008-10-30
IL173737A (en)	2012-04-30
CY1119609T1 (el)	2018-04-04
CA2536487C (en)	2011-10-25
SI3395340T1 (sl)	2019-08-30
EP1663182B2 (en)	2019-11-20
BR122018013029B1 (pt)	2022-04-12
AU2004279318A1 (en)	2005-04-21
AR045637A1 (es)	2005-11-02
AU2004279318B2 (en)	2010-02-25
TR201910177T4 (tr)	2019-08-21
EP3395339B8 (en)	2019-12-11
TR201910447T4 (tr)	2019-08-21
JP2007505108A (ja)	2007-03-08
WO2005034928A1 (en)	2005-04-21
ZA200602710B (en)	2007-04-25
EP3395338A1 (en)	2018-10-31
JP5940120B2 (ja)	2016-06-29
CY1121812T1 (el)	2020-07-31
EP3395340B8 (en)	2019-12-11
CN1946382A (zh)	2007-04-11
CN1946382B (zh)	2010-12-08
BRPI0414254B8 (pt)	2021-05-25
DK3260117T3 (da)	2019-07-01
BRPI0414254A (pt)	2006-11-07
HUE044822T2 (hu)	2019-11-28
PT3395339T (pt)	2019-07-15
JP2015007089A (ja)	2015-01-15
PT1663182E (pt)	2013-03-14
EP3260117A1 (en)	2017-12-27
PL2821067T3 (pl)	2018-02-28
EP3395340B1 (en)	2019-04-17
US20110136915A1 (en)	2011-06-09
TR201910180T4 (tr)	2019-07-22
JP5849015B2 (ja)	2016-01-27
ES2734057T3 (es)	2019-12-04
PL3395339T3 (pl)	2019-09-30
ES2735216T3 (es)	2019-12-17
EP3395339A1 (en)	2018-10-31
HUE035596T2 (en)	2018-05-28
HUE045411T2 (hu)	2019-12-30
DK2821067T3 (da)	2017-12-04
JP5026077B2 (ja)	2012-09-12
PL3395340T3 (pl)	2019-10-31
PT2821067T (pt)	2017-12-01
IS3027B (is)	2021-03-15
EP3395340A1 (en)	2018-10-31
AU2004279318C1 (en)	2020-06-25
DK3395340T3 (da)	2019-07-15
SI1663182T2 (sl)	2020-02-28
PL3395338T3 (pl)	2019-10-31
SI2821067T1 (en)	2018-03-30
BRPI0414254B1 (pt)	2021-03-02

Publication	Publication Date	Title
DK3395338T3 (da)	2019-07-22	Hurtigt opløsende formulering af cinacalcet-hcl
DK1763673T3 (da)	2014-07-28	Anvendelser af gelformuleringer
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
DK2172205T3 (da)	2014-07-14	Farmaceutisk formulering bestående af lanthan-forbindelser
DK1931315T3 (da)	2014-01-20	Depotformuleringer af nalbufin
DE602005012267D1 (de)	2009-02-26	N von geräten
ITMI20041252A1 (it)	2004-09-22	Composizioni perfluoroelastomeriche
FR2862654B1 (fr)	2006-02-10	Composition amylacee filmogene
DE602005008661D1 (de)	2008-09-18	Michael-addierungs Zusammensetzungen
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DK1670440T3 (da)	2014-07-07	HRT formuleringer
ATE382261T1 (de)	2008-01-15	Flüssige formulierung
IS8399A (is)	2006-04-05	Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
DK1516540T3 (da)	2012-11-26	Anvendelse af vitamin D-forbindelser
FI20030261A (fi)	2004-09-24	Iskulaite
DE602005008726D1 (de)	2008-09-18	Verwendet
CR9144A (es)	2007-11-23	Formulaciones de benzoxazoles sustituidos
DE602005016978D1 (de)	2009-11-12	Quecksilberfreisetzende Zusammensetzungen
DE602004004388D1 (de)	2007-03-08	Verdickbare zusammensetzungen
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
DE602004018858D1 (de)	2009-02-26	Emulsionszusammensetzung
DK1763520T3 (da)	2009-02-09	Anvendelse af trisubstituerede benzopyranoner
DK1541137T3 (da)	2010-04-26	Transdermalt delivery system af gestoden
DE602005024486D1 (de)	2010-12-16	Anthrapyridonfarbstoffe
DK3332789T3 (da)	2022-07-11	Cladribinkur til behandling af multipel sklerose